Relation of myeloperoxidase-463G/A polymorphism with metabolic syndrome and its component traits in Egyptian women

References

• Abu-Soud HM, Hazen SL. (2000). Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem, 275:5425–30
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120:1640–45
   PubMed Web of Science ®Google Scholar
• Austin GE, Lam L, Zaki SR, et al. (1993). Sequence comparison of putative regulatory DNA of the 5′ flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia, 7:1445–50
   PubMed Web of Science ®Google Scholar
• Chen L, Zhao S, Cheng G, et al. (2014). Meta-analysis of myeloperoxidase gene polymorphism and coronary artery disease susceptibility. J Cent S Univ Med Sci, 39:217–31
   Google Scholar
• Delporte C, Antwerpen PV, Vanhamme L, et al. (2013). Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediat Inflamm, 2013:971579
   PubMed Web of Science ®Google Scholar
• Dolley G, Lamarche B, Després JP, et al. (2008). Myeloperoxidase gene sequence variations are associated with low-density-lipoprotein characteristics. J Hum Genet, 53:439–46
   PubMed Web of Science ®Google Scholar
• Eiserich JP, Baldus S, Brennan ML, et al. (2002). Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science, 296:2391–4
   PubMed Web of Science ®Google Scholar
• Ergen A, İsbir S, Timirci Ö, et al. (2011). Effects of myeloperoxidase 2463 G/A gene polymorphism and plasma levels on coronary artery disease. Mol Biol Rep, 38:887–91
   PubMed Web of Science ®Google Scholar
• Ergen A, Karagedik H, Karaali ZE, Isbir T. (2014). An association between MPO -463 G/A polymorphism and type 2 diabetes. Folia Biol, 60:108–12
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. (1972). Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18:499–502
   PubMed Web of Science ®Google Scholar
• Ghattas MH, Mehanna ET, Mesbah NM, Abo-Elmatty DM. (2013). Association of estrogen receptor alpha gene polymorphisms with metabolic syndrome in Egyptian women. Metabolism, 62:1437–42
   PubMed Web of Science ®Google Scholar
• Grundy SM, Neeland IJ, Turer AT, Vega GL. (2014). Ethnic and gender susceptibility to metabolic risk. Metab Syndr Relat Disord, 12:110–16
   PubMed Web of Science ®Google Scholar
• Gupta V, Gupta A, Jafar T, et al. (2012). Association of TNF-alpha promoter gene G-308A polymorphism with metabolic syndrome, insulin resistance, serum TNF-alpha and leptin levels in Indian adult women. Cytokine, 57:32–6
   PubMed Web of Science ®Google Scholar
• Han TS, van Leer EM, Seidell JC, Lean ME. (1995). Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ, 311:1401–5
   PubMed Web of Science ®Google Scholar
• Joy T, Lahiry P, Pollex RL, Hegele RA. (2008). Genetics of metabolic syndrome. Curr Diab Rep, 8:141–8
   Google Scholar
• Karakas M, Koenig W, Zierer A, et al. (2012). Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med, 271:43–50
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Shao M, Wolski K, et al. (2014). Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound. Atherosclerosis, 232:377–83
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi SS, Mather K, et al. (2000). Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab, 85:2402–10
   PubMed Web of Science ®Google Scholar
• Kizaki M, Miller CW, Selsted ME, Koeffler HP. (1994). Myeloperoxidase (MPO) gene mutation in hereditary MPO deficiency. Blood, 83:1935–40
   PubMed Web of Science ®Google Scholar
• Kumar AP, Piedrafita FJ, Reynolds WF. (2004). Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the −463GA promoter polymorphism. J Biol Chem, 279:8300–315
   PubMed Web of Science ®Google Scholar
• Li D, Diao Y, Li H, et al. (2008). Association of the polymorphisms of MTHFR C677T, VDR C352T, and MPO G463A with risk for esophageal squamous cell dysplasia and carcinoma. Arch Med Res, 39:594–600
   PubMed Web of Science ®Google Scholar
• Liu YC, Chung CJ, Shiue HS, et al. (2013). Genetic polymorphisms of myeloperoxidase and their effect on hypertension. Blood Press, 22:282–9
   PubMed Web of Science ®Google Scholar
• Loria V, Dato I, Graziani F, Biasucci LM. (2008). Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm, 2008:135625
   Google Scholar
• Mäkelä R, Loimaala A, Nenonen A, et al. (2008). The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes. Clin Biochem, 41:532–7
   PubMed Web of Science ®Google Scholar
• Mandsorwale D, Nagtilak S, Lalchandani A, Srivastava AK. (2014). Role of -463 G/A genetic polymorphism & myeloperoxidase activity in prediction of cardiovascular disease. Sch J App Med Sci, 2:1402–7
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. (1985). Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28:412–19
   PubMed Web of Science ®Google Scholar
• Meuwese MC, Stroes ES, Hazen SL, et al. (2007). Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol, 50:159–65
   PubMed Web of Science ®Google Scholar
• Misra RR, Tangrea JA, Virtamo J, et al. (2001). Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett, 164:161–7
   PubMed Web of Science ®Google Scholar
• Nagra RM, Becher B, Tourtellotte WW, et al. (1997). Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol, 78:97–107
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. (2009). Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res, 50(Suppl):S346–51
   PubMed Web of Science ®Google Scholar
• Nikpoor B, Turecki G, Fournier C, et al. (2001). A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J, 142:336–9
   PubMed Web of Science ®Google Scholar
• Piedrafita FJ, Molander RB, Vansant G, et al. (1996). An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem, 271:14412–20
   PubMed Web of Science ®Google Scholar
• Povel CM, Boer JM, Reiling E, Feskens EJ. (2011). Genetic variants and the metabolic syndrome: a systematic review. Obes Rev, 12:952–67
   PubMed Web of Science ®Google Scholar
• Ramos RG, Olden K. (2008). The prevalence of metabolic syndrome among US women of childbearing age. Am J Public Heath, 98:1122–7
   PubMed Web of Science ®Google Scholar
• Reynolds WF, Rhees J, Maciejewski D, et al. (1999). Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol, 155:31–41
   PubMed Web of Science ®Google Scholar
• Rudolph V, Rudolph TK, Hennings JC, et al. (2007). Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radic Biol Med, 43:1189–96
   PubMed Web of Science ®Google Scholar
• Rutgers A, Heeringa P, Giesen JE, et al. (2003). Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms. Br J Haematol, 123:536–8
   PubMed Web of Science ®Google Scholar
• Saygili EI, Aksoy N, Pehlivan M, et al. (2009). Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma, 50:2030–7
   PubMed Web of Science ®Google Scholar
• Schabath MB, Spitz MR, Hong WK, et al. (2002). A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer, 37:35–40
   PubMed Web of Science ®Google Scholar
• Shao B, Oda MN, Bergt C, et al. (2006). Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem, 281:9001–4
   PubMed Web of Science ®Google Scholar
• Tang N, Wang Y, Mei Q. (2013). Myeloperoxidase G-463A polymorphism and susceptibility to coronary artery disease: a meta-analysis. Gene, 523:152–7
   PubMed Web of Science ®Google Scholar
• Uchimura K, Nagasaka A, Hayashi R, et al. (1999). Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus. J Diabetes Complications, 13:264–70
   PubMed Web of Science ®Google Scholar
• Undurti A, Huang Y, Lupica JA, et al. (2009). Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem, 284:30825–35
   PubMed Web of Science ®Google Scholar
• Vita JA, Brennan ML, Gokce N, et al. (2004). Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation, 110:1134–9
   PubMed Web of Science ®Google Scholar
• Xi B, Ruiter R, Chen J, et al. (2012). The ACE insertion/deletion polymorphism and its association with metabolic syndrome. Metabolism, 61:891–7
   PubMed Web of Science ®Google Scholar
• Zheng L, Nukuna B, Brennan ML, et al. (2004). Apolipoprotein A-1 is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subject with cardiovascular disease. J Clin Invest, 114:529–41
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang L, Zhou B, et al. (2006). Myeloperoxidase G–463A polymorphism and the risk of gastric cancer: a case-control study. Carcinogenesis, 27:2491–6
   PubMed Web of Science ®Google Scholar